AttendMe Owl Logo
AttendMe
Sign In
All Pathways
GastroenterologyManagement

C. difficile Infection Management (IDSA/SHEA 2021)

C. difficile Infection Management (IDSA/SHEA 2021): Suspected C. difficile Infection → Confirm Diagnosis → Initial Management → Assess Severity → Non-Se...

Pathway Overview

14 steps

Algorithm Steps

14 total

  1. 01Start

    Suspected C. difficile Infection

    ≥3 unformed stools in 24h + risk factors (antibiotics, hospitalization)

  2. 02Action

    Confirm Diagnosis

    Test only diarrheal stool (liquid/take shape of container)

    • NAAT (PCR) alone OR
    • GDH + toxin EIA (two-step) OR
    • NAAT + toxin EIA
    • Do NOT test for cure
    • Do NOT test asymptomatic patients
  3. 03Action

    Initial Management

    Start while awaiting results if high suspicion

    • STOP inciting antibiotic if possible
    • Contact precautions
    • Avoid antidiarrheals
    • Avoid PPIs if not strictly indicated
  4. 04Decision

    Assess Severity

    Classify as non-severe, severe, or fulminant

  5. 05Action

    Non-Severe CDI

    WBC ≤15,000 AND Cr <1.5

    • Fidaxomicin 200mg PO BID x 10 days (preferred)
    • OR Vancomycin 125mg PO QID x 10 days
    • Avoid metronidazole in adults
  6. 06Decision

    High Recurrence Risk?

    Age ≥65, immunocompromised, severe episode, previous CDI

  7. 07Action

    Consider Bezlotoxumab

    Anti-toxin B monoclonal antibody

    • Single IV dose during antibiotic treatment
    • Reduces recurrence by ~40%
    • High-risk patients: age ≥65, immunocompromised, severe CDI, prior CDI
  8. 08Outcome

    CDI Resolved

    Resolution = formed stools + no new diarrhea

  9. 09Action

    First Recurrence

    10-25% of patients recur

    • Fidaxomicin 200mg BID x 10 days (preferred over vanco)
    • OR Vancomycin taper:
    • 125mg QID x 10-14d, then
    • 125mg BID x 7d, then
    • 125mg daily x 7d, then
    • 125mg q2-3 days x 2-8 weeks
    • Consider FMT after
  10. 10Action

    Second or More Recurrence

    FMT strongly recommended

    • FMT after standard course of vancomycin (preferred)
    • FMT success rate 80-90%
    • If FMT not available: extended vancomycin taper + rifaximin
    • Fidaxomicin extended dosing (every other day weeks 2-4)
  11. Path rejoins step 08Shared downstream outcome
  12. 11Outcome

    Prevention Measures

    Antibiotic stewardship, hand hygiene, probiotics (limited evidence)

  13. Path rejoins step 08Shared downstream outcome
  14. 12Action

    Severe CDI

    WBC ≥15,000 OR Cr ≥1.5 OR age ≥65 with severe illness

    • Fidaxomicin 200mg PO BID x 10 days (preferred)
    • OR Vancomycin 125mg PO QID x 10 days
    • Consider vancomycin + IV metronidazole if critically ill
  15. Path rejoins step 06Shared downstream outcome
  16. 13Warning

    ⚠️ Fulminant CDI

    Hypotension, shock, ileus, or megacolon

    • Vancomycin 500mg PO/NG QID
    • + Metronidazole 500mg IV q8h
    • + Vancomycin enemas 500mg/100mL NS q6h if ileus
    • Surgical consult STAT
    • Consider colectomy
  17. 14Warning

    Surgical Evaluation

    For fulminant CDI refractory to medical therapy

    • Lactate >5, WBC >50,000
    • Toxic megacolon (colon >6cm)
    • Peritonitis, perforation
    • Subtotal colectomy with end ileostomy
    • OR Loop ileostomy with colonic lavage (may preserve colon)
  18. Path rejoins step 08Shared downstream outcome

Guideline Source

IDSA/SHEA Clinical Practice Guidelines for CDI in Adults: 2021 Update

DOI: 10.1093/cid/ciab549View Guideline

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • FMT availability varies by institution
  • Bezlotoxumab availability and cost
  • Severity criteria may evolve
  • Vancomycin taper schedules vary
  • Surgery decisions require multidisciplinary input

Applicable Regions

USGlobal

EU: ESCMID guidelines are similar

US: IDSA/SHEA 2021 is current standard

Version 1Next review: 2027-01-01

Related Gastroenterology Pathways

Acute Biliary Pancreatitis - GI Management (ACG 2024)

Management

Acute Cholangitis Management (Tokyo Guidelines 2018)

Emergency

Acute Liver Failure Management (AASLD 2023)

Emergency

Acute Mesenteric Ischemia Management (ESVS 2017)

Emergency

Next steps

Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.

Calculator

Glasgow-Blatchford Bleeding Score

Upper GI bleed risk stratification and need for intervention

Open page

Compare

AttendMe.ai vs UpToDate

See how this pathway workflow compares against UpToDate.

Open page

Commercial

Start free

Run the pathway in a live AttendMe account with citations and tracked usage.

Start free

Related Resources

All Clinical PathwaysClinical CalculatorsAI Chat with Auto-Detection

Frequently Asked Questions

What is the C. difficile Infection Management (IDSA/SHEA 2021)?

The C. difficile Infection Management (IDSA/SHEA 2021) is a management clinical algorithm for Gastroenterology. It provides a structured decision tree to guide clinical decision-making, based on IDSA/SHEA Clinical Practice Guidelines for CDI in Adults: 2021 Update.

What guideline is the C. difficile Infection Management (IDSA/SHEA 2021) based on?

This algorithm is based on IDSA/SHEA Clinical Practice Guidelines for CDI in Adults: 2021 Update (DOI: 10.1093/cid/ciab549).

What are the limitations of the C. difficile Infection Management (IDSA/SHEA 2021)?

Known limitations include: FMT availability varies by institution; Bezlotoxumab availability and cost; Severity criteria may evolve; Vancomycin taper schedules vary; Surgery decisions require multidisciplinary input. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the C. difficile Infection Management (IDSA/SHEA 2021) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free